Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
NASDAQ:ILMN
Illumina (ILMN) Stock Price & Analysis
4,053 Followers
ILMN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$86.49 - $190.13
Previous Close$114.49
Volume1.37M
Average Volume (3M)2.65M
Market Cap
$18.24B
Enterprise Value$20.41B
Total Cash (Recent Filing)$6.00M
Total Debt (Recent Filing)$2.18B
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 06, 2024EPS Estimate
$0.12Last Dividend Ex-Date
Jun 25, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-8.15
Shares Outstanding159,300,000
10 Day Avg. Volume5,823,582
30 Day Avg. Volume2,652,994
Standard Deviation0.12
R-Squared0.27
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)83.55
Price to Sales (P/S)3.84
Price to Cash Flow (P/CF)19.30
P/FCF Ratio22.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.53
Enterprise Value/Gross Profit7.44
Enterprise Value/Ebitda-703.73
Forecast
1Y Price Target
$142.90Price Target Upside24.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Illumina News
PremiumMarket News
QQQ ETF Update, 7/4/2024 
Bulls Say, Bears Say
Bulls Say
AcquisitionILMN announced the acquisition of Fluent Biosciences, bolstering its position as the most widely used analytical NGS platform for single cell experiments.
Growth StrategyThe acquisition bolsters ILMN's multi-omic growth strategy, which should strengthen their position in an increasingly competitive single cell market.
Strategic ShiftThis acquisition is viewed positively by investors as ILMN appears to be changing its strategy under new management to compete more effectively in life science tools.
Bears Say
Competitive PressuresThe next generation sequencing space continues to grow increasingly competitive, and Illumina’s hinted expansion into multi-omics may require substantial levels of investment.
Financial PerformanceIllumina's growth and margin profiles remain well-below their historical averages.
Revenue GuidanceConcerns around 2024 revenue guidance keep from changing the near-term rating.
---
Ownership Overview
1.88% Insiders
31.48% Mutual Funds
27.50% Other Institutional Investors
39.14% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $86.49 and its highest was $190.13 in the past 12 months.
What is Illumina’s market cap?
Currently, no data Available
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Aug 06, 2024 which is in 16 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on May 02, 2024. The company reported $0.087 earnings per share for the quarter, beating the consensus estimate of $0.042 by $0.045.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina pays a Notavailable dividend of $3.1 which represents an annual dividend yield of N/A. See more information on Illumina dividends here
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is $0.12.
How many shares outstanding does Illumina have?
Illumina has 159,300,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $0.087 in its last earnings report, beating expectations of $0.042. Following the earnings report the stock price went down -4.888%.
Which hedge fund is a major shareholder of Illumina?
Among the largest hedge funds holding Illumina’s share is Guardcap Asset Management Ltd. It holds Illumina’s shares valued at 284M.
---
Illumina Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$142.90 (24.81% Upside)
$142.90 (24.81% Upside)
Blogger Sentiment
Bullish
ILMN Sentiment 81%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 612.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.15%
12-Months-Change
Fundamentals
Return on Equity
-20.76%
Trailing 12-Months
Asset Growth
-14.99%
Trailing 12-Months
Company Description
Illumina
Incorporated in 1998, Illumina, Inc. is a California-based company which develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting.
---
ILMN Company Deck
---
ILMN Earnings Call
Q1 2024
0:00 / 0:00
---
ILMN Revenue Breakdown
68.45% Consumables
15.92% Service and other revenue
15.63% Instruments
---
ILMN Stock 12 Month Forecast
Average Price Target
$142.90
▲(24.81% Upside)
Technical Analysis
Best Analysts Covering ILMN
1 Year
1 Year Success Rate
24/30 ratings generated profit
1 Year Average Return
+17.12%
reiterated a buy rating 2 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +17.12% per trade.
---